Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 19.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,110 shares of the biopharmaceutical company’s stock after selling 1,476 shares during the quarter. ProShare Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $1,438,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jennison Associates LLC acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $61,160,000. Strategic Financial Concepts LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $41,529,000. Truist Financial Corp lifted its stake in shares of Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after purchasing an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after buying an additional 8,462 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Alnylam Pharmaceuticals by 7.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 38,997 shares of the biopharmaceutical company’s stock worth $9,176,000 after buying an additional 2,657 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.3%

Shares of ALNY opened at $292.58 on Thursday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $146.79 and a fifty-two week high of $304.39. The company has a market capitalization of $38.15 billion, a PE ratio of -134.83 and a beta of 0.17. The stock has a fifty day moving average of $256.73 and a two-hundred day moving average of $254.14. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. The firm’s revenue for the quarter was up 20.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.16) earnings per share. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Scotiabank increased their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a “sector outperform” rating in a report on Monday, March 31st. Royal Bank of Canada upped their price target on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a report on Friday, March 21st. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Chardan Capital increased their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. Finally, Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $319.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.